Jianke Invests in Singapore-Based Digital Health Company Biofourmis to Strengthen AI-Powered Chronic Disease Management Platform

VCBeat (WeChat: vcbeat) has learned that on May 21, Singapore-based digital health platform Biofourmis announced the completion of a $35 million Series B financing round, led by Sequoia Capital and joined by investors including China’s Jianke. Meanwhile, Biofourmis also announced that it will relocate its headquarters to Boston, USA, and expand its R&D operations to conduct clinical trials and broaden commercial partnerships.

Founded in 2015, Singapore-based Biofourmis has developed the Biovitals™ digital health platform, which successfully integrates wearable smart sensors, intelligent applications, medical databases, and a big data computing center. By leveraging artificial intelligence for data analysis, the platform delivers targeted, personalized healthcare services to patients, while assisting physicians in making more accurate and timely diagnoses, thereby improving treatment efficacy, patient survival rates, and quality of life.

It is understood that Biovital, the platform developed by Biofourmis, helps physicians better manage their patients, effectively improve patient adherence, and provide targeted and efficient care. By leveraging AI technology, it reduces the probability and cost of patient readmissions. Currently, the company’s data is derived from over 100,000 patients, a number that continues to grow. The Biovitals™ platform analyzes this data and provides it to physicians, while also sharing it with overseas commercial insurance companies to assess potential clients.

Kuldeep Singh Rajput, Founder and CEO of Biofourmis, stated: “At the core of our business is optimizing treatment regimens and enhancing patient care outcomes and health status. Over the past year, Biofourmis has achieved remarkable milestones. In addition to strengthening our health monitoring platform and establishing collaborations with numerous pharmaceutical companies worldwide, our team has made significant progress in product development. The new funding will enable Biofourmis to accelerate team expansion and product commercialization, while further demonstrating the efficacy of our digital health platform through research and development.”

This Series B financing round attracted not only renowned investment firms such as Sequoia Capital, Singapore’s EDBI, and MassMutual Ventures from the United States, but also Jianke, an online smart healthcare platform from China. Jianke’s investment has naturally drawn significant attention.

Xie Fangmin, CEO of Jianke, stated that Jianke has maintained deep strategic collaborations with renowned multinational pharmaceutical companies such as Pfizer, AstraZeneca, and Gilead. The company also closely monitors emerging enterprises in the healthcare sector and has always demonstrated strong enthusiasm for participating in internationally leading original technological innovations and R&D. Biofourmis has achieved rapid growth over the past few years, successfully translating the concept of digital health into tangible products through its robust R&D team, thereby showcasing the company’s strength and potential. “Currently, the global healthcare industry is evolving at an unprecedented pace, and digital health is gaining significant momentum,” he emphasized. He highlighted that Jianke’s current investment plan is future-oriented, aiming to deeply engage in the transformation of the healthcare industry through strategic partnerships with industry leaders, thereby seeking better healthcare solutions for both patients and physicians.

Founded in 2006, Jianke is the first B2C internet pharmaceutical enterprise legally authorized to operate in Guangdong Province. After more than a decade of rapid development, it has established strategic partnerships with thousands of large domestic pharmaceutical manufacturers, achieving direct drug supply. It is also one of the few companies in China that holds all three licenses: A, B, and C.

Now, with $130 million in Series B financing secured, Jianke is transitioning from an internet pharmaceutical veteran driven solely by pharmaceutical e-commerce to a health management service platform powered by the dual engines of “medical care + pharmaceuticals.” To date, Jianke Doctors has registered 100,000 physicians and served tens of millions of patients. Over the next five years, online medical services will remain a key strategic focus for Jianke.

As one of China’s leading smart health service platforms, Jianke has been actively exploring ways to provide patients with better solutions for chronic disease management, and this investment in an emerging digital health company is aligned with that goal. Since the beginning of this year, Jianke has made frequent moves in the fields of pharmaceutical e-commerce, mobile healthcare, internet hospitals, and chronic disease management.

Notably, earlier this year, Jianke signed a strategic partnership agreement with global pharmaceutical giant Pfizer for the “Online Family Doctor” project. The two parties will jointly explore innovative, integrated models of pharmaceutical and healthcare services, enabling more patients to benefit from mobile medical services. This latest investment in an emerging overseas digital health company signals that Jianke’s chronic disease management system, built around its internet hospital, is progressively evolving toward greater technological sophistication and intelligence.

Currently, Jianke is also seeking to introduce its digital health platform, Biovitals™, to China to better serve Chinese physicians and patients, address future challenges in heart failure patient management, and leverage this investment as a breakthrough to join forces with Biofourmis in tackling more medical challenges.